Please use this identifier to cite or link to this item: https://doi.org/10.1182/blood-2018-01-829424
DC FieldValue
dc.titleOncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
dc.contributor.authorSong, Tammy Linlin
dc.contributor.authorNairismagi, Maarja-Liisa
dc.contributor.authorLaurensia, Yurike
dc.contributor.authorLim, Jing-Quan
dc.contributor.authorTan, Jing
dc.contributor.authorLi, Zhi-Mei
dc.contributor.authorPang, Wan-Lu
dc.contributor.authorKizhakeyil, Atish
dc.contributor.authorWijaya, Giovani-Claresta
dc.contributor.authorHuang, Da-Chuan
dc.contributor.authorNagarajan, Sanjanaa
dc.contributor.authorChia, Burton Kuan-Hui
dc.contributor.authorCheah, Daryl
dc.contributor.authorLiu, Yan-Hui
dc.contributor.authorZhang, Fen
dc.contributor.authorRao, Hui-Lan
dc.contributor.authorTang, Tiffany
dc.contributor.authorWong, Esther Kam-Yin
dc.contributor.authorBei, Jin-Xin
dc.contributor.authorIqbal, Jabed
dc.contributor.authorGrigoropoulos, Nicholas-Francis
dc.contributor.authorNg, Siok-Bian
dc.contributor.authorChng, Wee-Joo
dc.contributor.authorTeh, Bin-Tean
dc.contributor.authorTan, Soo-Yong
dc.contributor.authorVerma, Navin Kumar
dc.contributor.authorFan, Hao
dc.contributor.authorLim, Soon-Thye
dc.contributor.authorOng, Choon-Kiat
dc.date.accessioned2021-11-23T04:23:31Z
dc.date.available2021-11-23T04:23:31Z
dc.date.issued2018-09-13
dc.identifier.citationSong, Tammy Linlin, Nairismagi, Maarja-Liisa, Laurensia, Yurike, Lim, Jing-Quan, Tan, Jing, Li, Zhi-Mei, Pang, Wan-Lu, Kizhakeyil, Atish, Wijaya, Giovani-Claresta, Huang, Da-Chuan, Nagarajan, Sanjanaa, Chia, Burton Kuan-Hui, Cheah, Daryl, Liu, Yan-Hui, Zhang, Fen, Rao, Hui-Lan, Tang, Tiffany, Wong, Esther Kam-Yin, Bei, Jin-Xin, Iqbal, Jabed, Grigoropoulos, Nicholas-Francis, Ng, Siok-Bian, Chng, Wee-Joo, Teh, Bin-Tean, Tan, Soo-Yong, Verma, Navin Kumar, Fan, Hao, Lim, Soon-Thye, Ong, Choon-Kiat (2018-09-13). Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. BLOOD 132 (11) : 1146-1158. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2018-01-829424
dc.identifier.issn00064971
dc.identifier.issn15280020
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/207360
dc.description.abstractMature T-cell lymphomas, including peripheral T-cell lymphoma (PTCL) and extranodal NK/T-cell lymphoma (NKTL), represent a heterogeneous group of non-Hodgkin lymphomas with dismal outcomes and limited treatment options. To determine the extent of involvement of the JAK/STAT pathway in this malignancy, we performed targeted capture sequencing of 188 genes in this pathway in 171 PTCL and NKTL cases. A total of 272 nonsynonymous somatic mutations in 101 genes were identified in 73% of the samples, including 258 single-nucleotide variants and 14 insertions or deletions. Recurrent mutations were most frequently located in STAT3 and TP53 (15%), followed by JAK3 and JAK1 (6%) and SOCS1 (4%). A high prevalence of STAT3 mutation (21%) was observed specifically in NKTL. Novel STAT3 mutations (p.D427H, E616G, p.E616K, and p.E696K) were shown to increase STAT3 phosphorylation and transcriptional activity of STAT3 in the absence of cytokine, in which p.E616K induced programmed cell death-ligand 1 (PD-L1) expression by robust binding of activated STAT3 to the PD-L1 gene promoter. Consistent with these findings, PD-L1 was overexpressed in NKTL cell lines harboring hotspot STAT3 mutations, and similar findings were observed by the overexpression of p.E616K and p.E616G in the STAT3 wild-type NKTL cell line. Conversely, STAT3 silencing and inhibition decreased PD-L1 expression in STAT3 mutant NKTL cell lines. In NKTL tumors, STAT3 activation correlated significantly with PD-L1 expression. We demonstrated that STAT3 activation confers high PD-L1 expression, which may promote tumor immune evasion. The combination of PD-1/PD-L1 antibodies and STAT3 inhibitors might be a promising therapeutic approach for NKTL, and possibly PTCL.
dc.language.isoen
dc.publisherAMER SOC HEMATOLOGY
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectHematology
dc.subjectPERIPHERAL T-CELL
dc.subjectCLASSICAL HODGKIN LYMPHOMA
dc.subjectDEATH LIGAND 1
dc.subjectRECURRENT MUTATIONS
dc.subjectSOMATIC MUTATIONS
dc.subjectLEUKEMIC TRANSFORMATION
dc.subjectGENETIC ALTERATIONS
dc.subjectSIGNALING PATHWAYS
dc.subjectJAK-STAT
dc.subjectBLOCKADE
dc.typeArticle
dc.date.updated2021-11-17T07:03:30Z
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.contributor.departmentDEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
dc.contributor.departmentBIOLOGICAL SCIENCES
dc.contributor.departmentPATHOLOGY
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.contributor.departmentMEDICINE
dc.description.doi10.1182/blood-2018-01-829424
dc.description.sourcetitleBLOOD
dc.description.volume132
dc.description.issue11
dc.description.page1146-1158
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Song TL. Blood 2018. STAT3 drives PDL1 in ENKTL.pdfPublished version1.37 MBAdobe PDF

CLOSED

Published

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.